Integrated Oncology Learning - Activity Details
To begin this acvivity, please choose a participation option at the bottom of this page.
Online Grand Rounds:
Optimizing Endocrine Therapy and Side Effect Management for Early-Stage Breast Cancer
Release Date: August 14, 2009
Expiration Date: August 14, 2010
Lecture Overview
Endocrine therapy has greatly improved outcome in patients with early-stage hormone receptor–positive breast cancer. However, the optimal strategy for using these hormone-targeted agents in the clinic remains controversial and is under active investigation. Topics recently addressed in reported trials include the up-front use of aromatase inhibitors (AIs) compared to switching from a selective estrogen receptor modulator, the optimal duration of endocrine therapy, and the sequence of agents that provides maximum benefit to the patient. Because AIs are associated with a decrease in bone density and a consequent increase in the risk of fracture, a variety of bone-targeted agents, including bisphosphonates and a monoclonal antibody to the receptor activator of nuclear factor-кB ligand, are being evaluated for their potential to maintain or restore bone health in this setting. Emerging data also suggest a role for bisphosphonates in the prevention of metastases in patients with early-stage breast cancer, a subject that is the focus of several ongoing trials.
The purpose of this activity is to update physicians with the most recent information on the use of endocrine therapy in early-stage breast cancer and bone-targeted agents in the management of therapy-related bone complications and the prevention of metastases.
Presented by Physicians’ Education Resource in conjunction with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
This educational activity is directed toward medical oncologists and other specialists practicing in the community or in an academic setting who are interested in the treatment of breast cancer. Physicians involved in the long-term management of patients with cancer as well as fellows, oncology physician assistants, oncology nurses, research nurses, and others with an interest in the treatment of patients with breast cancer are also invited to participate.
Upon completion of this educational activity, you should be able to:
- Compare alternative strategies for the use of AIs as adjuvant therapy in postmenopausal women with early-stage hormone receptor–positive breast cancer
- Evaluate the efficacy of bone-targeted therapies, including bisphosphonates and novel agents, in patients with an increased risk of fractures who are receiving adjuvant AI therapy for hormone receptor–positive breast cancer
- Discuss the utility of bisphosphonates for the prevention of metastases in patients with early-stage breast cancer
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View the Flash video presentation and slides.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
You will be asked to login
or create an account.